Zhipeng Li

Zhipeng Li

Auto-generated profile, based on publicly available information

Zhipeng Li

Taizhou University, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in World Journal of Clinical Cases
Verified
Journal Article
Open access
LXLei Xiang
Lei Xiang
HLHan Li
Han Li
QXQi-Qi Xie
Qi-Qi Xie
CSChing Sin Siau
Ching Sin Siau
ZXZhi Xie
Zhi Xie
SWShuai-Bin Wang
Shuai-Bin Wang
This article reviews the research progress of rehabilitation treatment and nursing care of patients with neurogenic bladder after spinal cord injury, in order to provide reference for the rehabilitation treatment and nursing care of patients. We reviewed recent medical literature on patients with neurogenic bladder, focusing on neurogenic bladder caused by spinal cord injury. We analyzed 30 recent of publications in patients with neurogenic bladder after spinal cord injury, in addition to reviewing and evaluating the commonly used rehabilitation nursing methods for neurogenic bladder. Psychological counseling is a vital aspect which cannot be neglected in the process of neurogenic bladder rehabilitation. Hitherto, the commonly used drug and surgical treatments may have negatively impacted the mental health of patients in varying degrees. However, in clinical practice, applying intermittent catheterization in patients who have neurogenic bladder with spinal cord injury may help improve patients’ life quality, mitigate psychological burden, and reduce negative emotions.

1 October 2012 in International Immunopharmacology
Verified
Journal Article
Closed access
ZLZhipeng Li
Zhipeng Li
JHJin-Feng Hu
Jin-Feng Hu
MSMingna Sun
Mingna Sun
HJHaijie Ji
Haijie Ji
SCShi-feng Chu
Shi-feng Chu
NCNaihong Chen
Naihong Chen

17 August 2022 in Journal of Clinical Psychology
Verified
Journal Article
Closed access
SWShuo Wang
Shuo Wang
XSXuliang Shi
Xuliang Shi
YGYihan Guo
Yihan Guo
ZLZihan Li
Zihan Li
AWAnqi Wang
Anqi Wang
ZLZhipeng Li
Zhipeng Li

4 June 2022 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
XRXiaohua Ren
Xiaohua Ren
RPRoujun Pan
Roujun Pan
ZLZhipeng Li
Zhipeng Li
LHLian-Ping He
Lian-Ping He

1 May 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
JLJiayao Li
Jiayao Li
BCBinhao Cao
Binhao Cao
SYShuxia Yu
Shuxia Yu
CLChengjin Li
Chengjin Li
MXMengen Xue
Mengen Xue
CJChongqiang Jin
Chongqiang Jin
Diabetes mellitus, particularly type 2 diabetes, has been associated in some studies with increased osteoarthritis (OA) risk, greater symptom burden, and structural progression; however, epidemiological evidence remains heterogeneous, and the extent to which diabetes independently contributes to OA after accounting for obesity, adiposity, physical inactivity, and other metabolic confounders remains debated. In metabolically susceptible patients, chronic hyperglycemia, insulin resistance, carbonyl stress, and low-grade inflammation may contribute to disruption of the joint microenvironment. One proposed mechanism involves the accumulation of advanced glycation end products (AGEs), which can cross-link with type I/II collagen and may increase extracellular matrix crosslinking and stiffness. Through these biochemical and biomechanical effects, the AGE–collagen axis may influence chondrocyte mechanotransduction, inflammatory signaling, matrix turnover, and cell survival, thereby providing a plausible but not yet fully validated link between systemic metabolic dysfunction and OA-relevant structural degeneration. Recent advances in biomaterials may offer experimental and translational strategies to modulate the glycated, inflamed, and mechanically altered joint microenvironment. These approaches include stiffness-tunable and stimuli-responsive hydrogels, nanocarriers designed to deliver anti-AGE agents or AGE-cleaving enzymes, osteochondral gradient scaffolds that mimic native tissue transitions, and immunomodulatory materials that may attenuate local inflammation. At present, these interventions should be viewed primarily as preclinical or early translational strategies rather than established disease-modifying therapies. This review discusses the potential molecular and biomechanical implications of the AGE–collagen axis in diabetes-related OA, critically evaluates emerging biomaterials-based therapeutic approaches, and highlights preclinical evaluation models and outcome measures. Finally, we outline key translational challenges—including targeted delivery, long-term safety of degradation products, metabolic heterogeneity, patient stratification, and integration with systemic therapies—and propose methodological frameworks to support the future development of clinically testable biomaterials interventions.